Royal College of Surgeons in Ireland
Browse
PAR-4 – a novel marker of luminal A breast cancer …..pdf (847.43 kB)

PAR-4 – a novel marker of luminal A breast cancer – is down-regulated by the steroid receptor co-activator SRC-1

Download (847.43 kB)
journal contribution
posted on 2023-08-02, 09:56 authored by Aoife Cahalin, Jarlath BolgerJarlath Bolger, Claire Walsh, Damien McCartan, Marie McIlroyMarie McIlroy, Arnold HillArnold Hill, Leonie YoungLeonie Young

Introduction: Prostate apoptosis response-4 (PAR-4, PAW-R, PKC apoptosis WT1 regulator) is a gene coding for a tumour suppressor protein involved in the selective apoptosis of cancer cells. Although well described in renal cell carcinomas and prostate cancer, little is known about its role and regulation in breast cancer.

Methods: Western blotting techniques looked at the association between PAR-4 expression and breast cancer sub-type, and at the effects of steroid receptor co-activator-1 (SRC-1) on PAR-4 expression. Functional assays (3D cell culture and adhesion independent growth) investigated the role of PAR-4 in breast cancer cells and immunohistochemistry looked at the clinical correlations of PAR-4 positivity in our patient cohort.

Results: The results show that PAR-4 is down-regulated by SRC-1 in endocrine-resistant cell lines and they validate its use as a marker of good disease-free survival, both in vitro and in vivo. In addition, the functional assays provide evidence that PAR-4 may play a role in maintaining a well-differentiated phenotype in breast cancer cell lines.

Conclusion: The results suggest that PAR-4 expression is a marker of good disease-free survival, or conversely, that the loss of PAR-4 expression would signal tumour progression to a more aggressive phenotype. The identification of such markers is important in the development of more personalised forms of treatments.

Funding

Breast Cancer Ireland

History

Comments

The original article is available at http://www.rcsismj.com/ Part of the RCSIsmj collection 2012-3 https://doi.org/10.25419/rcsi.c.6767511.v2

Published Citation

Cahalin A. et al. PAR-4 – a novel marker of luminal A breast cancer – is down-regulated by the steroid receptor co-activator SRC-1. RCSIsmj. 2013;6(1):37-41

Publication Date

2013

Department/Unit

  • Beaumont Hospital
  • Surgery
  • Undergraduate Research

Publisher

RCSI University of Medicine and Health Sciences

Version

  • Published Version (Version of Record)